Senzo, originally known as Orphidia, is a bio-med company focused on revolutionizing rapid diagnostic testing. Founded with the mission to make accurate and timely medical diagnostics more accessible, Senzo has developed a portable device capable of running multiple common lab tests simultaneously. Their lateral flow test technology offers PCR-level accuracy with results available within minutes at a fraction of the cost. The company targets prevalent diseases and infections such as COVID-19, HIV, Flu A/B, Hepatitis C, Tuberculosis, and C. Difficile.
Senzo's innovative approach has attracted notable investors and industry experts who recognize the potential impact of their technology on global health. The company's key achievements include the development and successful deployment of their rapid diagnostic platform in various healthcare settings. By enabling earlier and more widespread diagnoses, Senzo is making significant strides in improving patient outcomes and reducing healthcare costs worldwide.
